Management of cardiac diseases in liver transplant recipients: Comprehensive review and multidisciplinary practice-based recommendations.

Autor: Izzy M; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University, Nashville, Tennessee, USA., Fortune BE; Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, New York, USA., Serper M; Department of Medicine, Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Bhave N; Department of Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA., deLemos A; Department of Medicine, Division of Hepatology, Atrium Health, Charlotte, North Carolina, USA., Gallegos-Orozco JF; Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Utah School, Salt Lake City, Utah, USA., Guerrero-Miranda C; Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, Texas, USA., Hall S; Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, Texas, USA., Harinstein ME; Department of Medicine, Division of Cardiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Karas MG; Department of Medicine, Division of Cardiology, Weill Cornell Medical College, New York, New York, USA., Kriss M; Department of Medicine, Division of Gastroenterology and Hepatology, University of Colorado, Aurora, Colorado, USA., Lim N; Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA., Palardy M; Department of Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA., Sawinski D; Department of Medicine, Division of Nephrology and Hypertension, Weill Cornell Medical College, New York, New York, USA., Schonfeld E; Department of Medicine, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, New York, USA., Seetharam A; Department of Medicine, Division of Gastroenterology and Hepatology, Banner - University Medical Center Phoenix, Phoenix, Arizona, USA., Sharma P; Department of Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA., Tallaj J; Department of Medicine, Division of Cardiovascular Disease, University of Alabama, Birmingham, Alabama, USA., Dadhania DM; Department of Medicine, Division of Nephrology and Hypertension, Weill Cornell Medical College, New York, New York, USA., VanWagner LB; Department of Medicine, Division of Gastroenterology & Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.; Department of Preventive Medicine, Division of Epidemiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Jazyk: angličtina
Zdroj: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons [Am J Transplant] 2022 Dec; Vol. 22 (12), pp. 2740-2758. Date of Electronic Publication: 2022 Apr 22.
DOI: 10.1111/ajt.17049
Abstrakt: Cardiac diseases are one of the most common causes of morbidity and mortality following liver transplantation (LT). Prior studies have shown that cardiac diseases affect close to one-third of liver transplant recipients (LTRs) long term and that their incidence has been on the rise. This rise is expected to continue as more patients with advanced age and/or non-alcoholic steatohepatitis undergo LT. In view of the increasing disease burden, a multidisciplinary initiative was developed to critically review the existing literature (between January 1, 1990 and March 17, 2021) surrounding epidemiology, risk assessment, and risk mitigation of coronary heart disease, arrhythmia, heart failure, and valvular heart disease and formulate practice-based recommendations accordingly. In this review, the expert panel emphasizes the importance of optimizing management of metabolic syndrome and its components in LTRs and highlights the cardioprotective potential for the newer diabetes medications (e.g., sodium glucose transporter-2 inhibitors) in this high-risk population. Tailoring the multidisciplinary management of cardiac diseases in LTRs to the cardiometabolic risk profile of the individual patient is critical. The review also outlines numerous knowledge gaps to pave the road for future research in this sphere with the ultimate goal of improving clinical outcomes.
(Darshana M. Dadhania and Lisa B. VanWagner contributed equally.© 2022 The American Society of Transplantation and the American Society of Transplant Surgeons.)
Databáze: MEDLINE
Externí odkaz: